Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update

Cue Biopharma, Inc. (NASDAQ:CUE) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,800,000 shares, an increase of 6.7% from the September 15th total of 3,560,000 shares. Based on an average daily trading volume, of 577,000 shares, the short-interest ratio is currently 6.6 days.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CUE shares. Piper Sandler dropped their price target on Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. JMP Securities cut their target price on shares of Cue Biopharma from $15.00 to $2.00 and set a “market outperform” rating for the company in a research note on Friday, July 26th. Finally, Stifel Nicolaus decreased their price target on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cue Biopharma has an average rating of “Buy” and a consensus price target of $5.00.

Cue Biopharma Price Performance

NASDAQ:CUE traded up $0.04 during mid-day trading on Thursday, reaching $1.11. The stock had a trading volume of 312,208 shares, compared to its average volume of 409,055. Cue Biopharma has a 12 month low of $0.45 and a 12 month high of $3.25. The stock has a market capitalization of $53.99 million, a PE ratio of -1.03 and a beta of 1.96. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.06 and a quick ratio of 2.06. The stock has a 50-day simple moving average of $0.75 and a two-hundred day simple moving average of $1.17.

Cue Biopharma (NASDAQ:CUE) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.09. Cue Biopharma had a negative return on equity of 142.93% and a negative net margin of 566.02%. The company had revenue of $2.66 million for the quarter, compared to analyst estimates of $1.12 million. During the same quarter last year, the company posted ($0.29) EPS. On average, equities analysts anticipate that Cue Biopharma will post -0.85 earnings per share for the current year.

Institutional Trading of Cue Biopharma

A number of hedge funds have recently added to or reduced their stakes in CUE. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Cue Biopharma during the second quarter valued at about $66,000. Wedmont Private Capital raised its holdings in Cue Biopharma by 100.0% in the 1st quarter. Wedmont Private Capital now owns 40,000 shares of the company’s stock valued at $76,000 after buying an additional 20,000 shares during the last quarter. Good Life Advisors LLC boosted its position in Cue Biopharma by 23.1% during the 3rd quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock worth $303,000 after buying an additional 75,000 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Cue Biopharma by 7.1% during the 1st quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock worth $4,316,000 after acquiring an additional 150,457 shares during the last quarter. Institutional investors and hedge funds own 35.04% of the company’s stock.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.